C12Y 207/11011
Camp-dependent protein kinase
Official title: cAMP-dependent protein kinase (2.7.11.11)
C12Y207/11011 (Camp-dependent protein kinase) appears on 18 US grants and 37 published applications in this corpus.
Search patents in C12Y- Granted patents
- 18
- Published applications
- 37
- Assignees
- 16
- Inventors
- 64
- Latest grant
- 20 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 1 | 1 |
| 2013 | 0 | 2 |
| 2014 | 0 | 2 |
| 2015 | 1 | 2 |
| 2016 | 4 | 6 |
| 2017 | 1 | 7 |
| 2018 | 1 | 1 |
| 2019 | 3 | 0 |
| 2020 | 2 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 2 |
| 2024 | 0 | 3 |
| 2025 | 1 | 0 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- T-cell receptor for treating fibrolamellar hepatocellular carcinoma20 Jan 2026US 12,528,853 B2St. Jude Children?S Research Hospital
- Modified peptides and associated methods of use18 Nov 2025US 12,473,332 B2
- Modified peptides and associated methods of use21 Nov 2023US 11,820,837 B2Advanced Technologies for Novel Therapeutics, LLC
- Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer13 Oct 2020US 10,800,828 B2The Scripps Research Institute
- MTOR kinase mutations and methods of use thereof4 Feb 2020US 10,551,384 B2Rutgers, The State University of New Jersey
- Compositions and methods for enhancing drug resistance in cells10 Sep 2026US 2026/0265712 A1Medici Therapeutics, Inc.
- Microbial cell factories producing vitamin b compounds7 Nov 2024US 2024/0368659 A1
- Nucleic acid molecules22 Aug 2024US 2024/0277834 A1AstraZeneca AB
- Modified peptides and associated methods of use14 Mar 2024US 2024/0083948 A1Advanced Technologies for Novel Therapeutics, LLC
- Methods and compositions for treating cancer14 Sep 2023US 2023/0285556 A1Omeros Corporation
Most cited
By later US patents
- Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses117US 7,550,143 B2IBC Pharmaceuticals, Inc. · 2009
- Dock-and-lock (DNL) vaccines for cancer therapy68US 7,901,680 B2IBC Pharmaceuticals, Inc. · 2011
- Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses45US 8,163,291 B2IBC Pharmaceuticals, Inc. · 2012
- T-cell redirecting bispecific antibodies for treatment of disease39US 9,315,567 B2IBC Pharmaceuticals, Inc. · 2016
- Tetrameric cytokines with improved biological activity6US 9,931,413 B2IBC Pharmaceuticals, Inc. · 2018